Document:

Exhibit 10.1

 

	 	
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

	 	
1. CONTRACT ID CODE

 

 

	 	 	
PAGE  OF  PAGES

	 	
1

	
2

	 	
2. AMENDMENT/MODIFICATION NO.

 

0015

	 	 	
3. EFFECTIVE DATE

 

See Block 16C

	 	
4. REQUISITION/PURCHASE REQ. NO.

 

OS221262

	 	5. PROJECT NO. (if applicable)
	 	
6. ISSUED BY

	 	CODE	
ASPR-BARDA

	 	
7. ADMINISTERED BY (if other than Item 6)

		CODE	
ASPR-BARDA02

	 	
 

ASPR-BARDA

200 Independence Ave., S.W.

Room 640-G

Washington DC 20201

 

	 	
 

ASPR-BARDA

330 Independence Ave, SW, Rm G640

Washington DC 20201

 

	 	
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP code)

 

SIGA TECHNOLOGIES, INC. 1385150

SIGA TECHNOLOGIES, INC.           35 E 6

35 E 62ND ST

NEW YORK NY 100658014

	 	
(x)

	 	
9A. AMENDMENT OF SOLICITATION NO.

	 	 
	 	 	 	
9B. DATED (SEE ITEM 11)

	 		 	
 

	 	 	 	
X

	 	
10A. MODIFICATION OF CONTRACT/ORDER NO.

HHSO10020110001C

	 	 	 	 	 	 	 	 	
10B. DATED (SEE ITEM 13)

 

05/13/2011

	 	
CODE

1385150

	 	FACILITY CODE	 	 

		
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	 	
☐  The above numbered solicitation is amended as set forth in Item 14.  The hour and date specified for receipt of Offers          ☐ is extended,      ☐ is not extended Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:  (a) By completing items 8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	 	
12. ACCOUNTING AND APPROPRIATION DATA   (if required) 

2018.199TWNP.26402

	Net Increase:  	$50,000,000.00

		
13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS.  IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	 	
CHECK ONE

	 	
A.    THIS CHANGE ORDER IS ISSUED PURSUANT TO:  (Specify authority)  THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	 	 
	 	 	 	
B.    THE ABOVE NUMBERED CONRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.)  SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b)

 

	 	
X

	 	
C.     THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTOPURSUANT TO AUTHORITY OF:

52.217-7 Option for Increased Quantity Separately Priced Line Item; FAR 1.605-1 – Mutual Agreement

	 	 	 	
D.          OTHER (Specify type of modification and authority)

 

	 	
E. IMPORTANT:          Contractor          ☐ is not,          ☒ is required to sign this document and return      1       copies to the issuing office.

		
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible)

 

Tax ID Number:          13-3864870

DUNS Number:          932651516

PURPOSE:       This modification is to exercise option CLIN 0011, B.5. Price schedule, Payment for FDA Approval for extension to 84-Month Expiry Product, as described in Section C.7.1 (NSP).

 

FUNDS ALLOTTED PRIOR TO MOD #15          $472,320,688.00

FUNDS ALLOTTED WITH MOD #15                 $50,000,000.00

TOTAL FUNDS ALLOTTED TO DATE              $522,320,688.00 (Changed)

 

EXPIRATION DATE:  September 24, 2020          (Unchanged)

Continued ...

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect

		
15A. NAME AND TITLE OF SIGNER (Type or print)

 

Dennis E. Hruby CSO

	 	
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

 

ELIZABETH STEINER

	 	
15B. CONTRACTOR/OFFEROR

 

/s/ Dennis E. Hruby

	 	
15C. DATE SIGNED

 

 

30 Jul 2018

	 	

16B. UNITED STATES OF AMERICA

 

/s/ Elizabeth Steiner

	 	
16C. DATE SIGNED

 

 

7/30/18

	 	
(Signature of person authorized to sign)

	 	
(Signature of Contracting Officer)

	
NSN 7540-01-152-8070

	
STANDARD FORM 30 (REV. 10-83)

	
Previous edition unusable

	
Prescribed by GSA

	
 

	
FAR (48 CFR) 53.243

 

	 	
CONTINUATION SHEET

	 	
REFERENCE NO. OF DOCUMENT BEING CONTINUED

 

HHSO100201100001C/0015

	
PAGE     OF

	
2

	
2

	 	
NAME OF OFFEROR OR CONTRACTOR

 

SIGA TECHNOLOGIES, INC. 1385150

	 	
ITEM NO.

(A)

	 	
SUPPLIES/SERVICES

(B)

	
QUANTITY

(C)

	
UNIT

(D)

	
UNIT PRICE

(E)

	
AMOUNT

(F)

	 	 	 	
CONTRACT FUNDED THROUGH September 24, 2020 (Unchanged)

 

Total contract value is changed from Not To Exceed $472,320,688.00 by $50,000,000.00 to $522,320,688.00.

 

1)   This option is being exercised in accordance with Statement of Objectives, Section C.7.1.1 and corresponding Section B.5. Price schedule, CLIN 0011, because SIGA completed the contract requirement for FDA Approval for extension to 84-Month Expiry Product on July 13, 2018 by receiving NDA approval from the FDA.

2)   By exercising the option for CLIN 0011 under the terms of this contract the total amount being obligated under this modification for this option FFP CLIN (0011) is $50,000,000 (FFP).

 

All other terms and conditions of contract HHSO1002011000010 remain unchanged.

 

END OF MODIFICATION 0015 TO HHSO100201100001C

Delivery:  06/07/2018

Delivery Location Code:  HHS/OS/ASPR

HHS/OS/ASPR

200 C St SW

WASHINGTON DC 20201 US

 

Appr. Yr.:  2018 CAN:  199TWNP Object Class:  26402

FOB:  Destination

Period of Performance:  06/28/2016 to 09/24/2020

 

Add Item 7 as follows:

 

	 	 	 	 
	 	 	 	
ASPR-18-02825 -- Exercise Option CLIN 0011 under

SIGA Technologies contract HHSO100201100001C

Obligated Amount:  $50,000,000.00

	 	 	 	
$50,000,000.00

	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 

		
NSN 7540-01-152-8067    

	
OPTIONAL FORM 336 (4-86)

	 
	 	
 

	
Sponsored by GSA

	 
	 	
 

	
FAR (48 CFR) 53.110life-ex101_6.htm

Exhibit 10.1

July 16, 2018

 

 

Ms. Jill Broadfoot

[***]

[***]

 

Re: Revised Offer of Employment:

Removal of Contingency in Letter Dated June 29, 2018 - Formal Background Check Successfully Completed 

 

Dear Jill,

 

This letter is a formal offer setting forth the principal terms for you to join aTyr Pharma, Inc. (“aTyr” or the “Company”), a Delaware corporation, which is located in San Diego, California.  

 

	
Position:
	
Chief Financial Officer

 

	
Location:
	
San Diego, CA

 

	
Status:
	
Full-Time, Exempt.  This means you are paid for the job and not by the hour.  Accordingly, you will not receive overtime pay.

 

	
Reporting to:
	
Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer

 

	
Base Salary Rate:
	
$14,583.34 semi-monthly (which equals $350,000.16 per year) less applicable withholdings, paid in accordance with Company’s normal payroll practices.  Future adjustments in compensation, if any, will be made by the Company in its sole and absolute discretion.

 

	
Target Bonus:
	
Your annual target bonus will be 40% of your base salary based upon the achievement of your individual goals, the achievement of team goals and the achievement of corporate goals established by the Company in its sole discretion.  Your annual target bonus is subject to review and approval by the aTyr Board of Directors or Compensation Committee of the Board of Directors.  Your 2018 bonus will be prorated based upon your hire date. You must be employed by the Company at the time the bonus is paid out to earn and receive the bonus.  

 

 

 

 

 

 

Ms. Jill Broadfoot

July 16, 2018

Page 2

 

 

	
Equity: 
	
As promptly as practicable after commencement of your employment with the Company, and subject to approval by the Board of Directors (or the Compensation Committee of the Board of Directors), you will be granted an option to purchase 200,000 shares of the Common Stock of the Company (the “Option”).  Subject to your continued full-time employment with the Company, the shares subject to the Option shall vest over a four (4) year period from your employment start date, with a one (1) year cliff, such that one-fourth (1/4) of the shares subject to the Option shall vest on the first year anniversary of your employment start date and the remainder of the shares shall thereafter vest in equal monthly installments over the subsequent three (3) years.  The exercise price per share of the Option shall be determined based on the closing price of the Common Stock as reported on NASDAQ on the effective date of the grant.  The specific terms and conditions of your Option will be subject to the terms set forth in a Stock Option Agreement between you and the Company. 

 

	
Severance Policy:
	
You will be eligible for aTyr’s Executive Severance and Change in Control Policy, including severance provisions for “Not for Cause” separations as well as “Change in Control” separations.  The specifics of the plan will be provided to you.

 

	
Benefits:
	
You will be entitled to receive standard medical, life and dental insurance benefits for yourself and your dependents in accordance with Company policy.  Company reserves the right to change or eliminate these benefits on a prospective basis at any time.

 

	
401(k) Plan:
	
You will be eligible to participate in the aTyr Pharma, Inc. 401(k) Savings Plan immediately following the start of your employment.  

 

Vacation & 

	
Sick Time:
	
You will be entitled to accrue 15 days of vacation per year as a Full-Time employee.  You will have 6 days of sick time available each year.

 

	
Holidays:
	
You will be eligible for aTyr’s paid holidays.  The schedule is published prior to the beginning of each calendar year.

 

	
Employment at Will:
	
Your employment will be at-will, which means it may be terminated at any time by you or the Company for any reason, with or without cause, and that your employment is not for any specific period of time.  Any change to the 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 

Phone 858 731 8389   Fax 858 731 8394

 

Ms. Jill Broadfoot

July 16, 2018

Page 3

		
at-will employment relationship must be by a specific, written agreement signed by you and the Company’s Chief Executive Officer.

 

	
 Start Date:
	
Monday, July 30, 2018

 

As a condition of your employment, you will be required to sign and abide by our Employee Nondisclosure and Assignment Agreement (the “Employee NDA”) when you begin your employment.  A copy is attached for your reference.  As a condition of your employment, you will also be required to abide by the Company’s code of conduct and other policies applicable to employees as set forth in the Company’s employee handbook in effect from time to time.  A copy will be made available to you during your employment.  In addition, in order to comply with the Immigration Reform and Control Act of 1986, within three (3) days of your Start Date you will be required to provide sufficient documentation to verify your identity and legal authorization to work in the United States. Please bring with you on your Start Date, the original of one of the documents noted in List A or one document from List B and one document from List C as itemized in the enclosed “Lists of Acceptable Documents”.  If you do not have the originals of any of these documents, please contact me immediately.

 

In the event of any dispute or claim relating to or arising out of your employment relationship with the Company, this agreement, or the termination of your employment with the Company for any reason (including, but not limited to, any claims of breach of contract, defamation, wrongful termination or age, sex, sexual orientation, race, color, national origin, ancestry, marital status, religious creed, physical or mental disability or medical condition or other discrimination, retaliation or harassment), you and the Company agree that all such disputes shall be fully resolved by confidential, binding arbitration conducted by a single arbitrator through the American Arbitration Association (“AAA”) under the AAA’s Employment Arbitration Rules and Mediation Procedures then in effect, which are available online at the AAA’s website at www.adr.org.  The arbitrator shall permit adequate discovery and is empowered to award all remedies otherwise available in a court of competent jurisdiction and any judgment rendered by the arbitrator may be entered by any court of competent jurisdiction.  By executing this letter, you and the Company are both waiving the right to a jury trial with respect to any such disputes.  Company shall bear the costs of the arbitrator, forum and filing fees.  Each party shall bear its own respective attorney fees and all other costs, unless otherwise provided by law and awarded by the arbitrator.

 

It is aTyr’s policy to respect fully the rights of your previous employers in their proprietary or confidential information.  No employee is expected to disclose, or is allowed to use for aTyr’s  purposes, any confidential or proprietary information he or she may have acquired as a result of previous employment.

 

 

 

 

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 

Phone 858 731 8389   Fax 858 731 8394

 

Ms. Jill Broadfoot

July 16, 2018

Page 4

I am pleased to extend this offer to you and look forward to your acceptance.  Please sign and return the enclosed copy of this offer letter as soon as possible to indicate your agreement with the terms of this offer.  This offer will lapse if not signed and returned by Thursday, July 5, 2018.

 

Once signed by you, this letter, together with the Employee NDA, will constitute the complete agreement between you and the Company regarding employment matters and will supersede all prior written or oral agreements or understandings on these matters.

 

Our mission is to discover life-changing therapies with relentless determination for people with grave maladies where others fall short.  I believe you will be able to make an immediate contribution to this mission and I think you will enjoy the rewards of working for an innovative, fast-paced company.  One of the keys to our success is top people.  We hope you accept our offer to be one of those people.

 

Yours sincerely,

 

/s/ Sanjay S. Shukla

Sanjay S. Shukla, M.D., M.S.

President and Chief Executive Officer

 

Enclosures

 

I accept the terms of employment as described in this offer letter, including the agreement to arbitrate claims, dated            July 16, 2018          and will start my employment on      July 30, 2018  .  I confirm that by my start date at aTyr Pharma, Inc. I will be under no contract or agreement with any other entity which would in any way restrict my ability to work at aTyr Pharma, Inc. or perform the functions of my job for aTyr, including, but not limited to, any employment agreement and/or non-compete agreement.

 

	
/s/ Jill M. Broadfoot
	
DateJuly 17, 2018

Jill Broadfoot

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite #250   San Diego   CA   92121 

Phone 858 731 8389   Fax 858 731 8394

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]